Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-18

Development of antibiofilm coatings for implants

Objective

The aim of the SME-driven COATIM consortium is to tackle the increasing problem of infections due to biofilms, groups of microorganisms that stick together on different surfaces within the human body and escape conventional antibiotic treatment. Biofilms are typically found on medical devices like implants. The most recent generation of implants with open porosity enable fast osseointegration, but also present an increased risk of microbial biofilm-associated infection. Biofilm-associated infections are responsible for 15-25% of implant failure, and necessitate burdensome and costly revision surgery. The latter is estimated to represent a supplementary medical cost of €800m/year in Europe without taking into account the pain and distress of the patients, indicating that any significant reduction of this type of implant failure is highly recommended. Until now, biocidal implant coatings have been developed that are based on either the release of silver ions, which are toxic upon accumulation, or on conventional antibiotics that have poor activity against microorganisms in biofilms. Therefore, COATIM aims to develop the next generation of implant coatings containing novel potent proprietary antibiofilm molecules (ABMs) with inhibitory activity against microbial biofilms. In COATIM, these ABMs are grafted or deposited on small titanium implant substrates, as a model for dental and orthopaedic implants. Next, the ABM-coated implants are evaluated for in vitro and in vivo activity in resisting microbial infection without compromising osseointegration. Finally, the ABM-coating is applied on complex orthopaedic and dental implants, allowing the exploitation of the results by industry. In parallel, the antibiofilm mode of action of the ABMs is unraveled. COATIM contributes to a dynamic and competitive knowledge-based economy, sustainable development, and serves the needs of the SME-intensive medical technology products market in Europe.

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN
EU contribution
€ 1 314 442,94
Address
OUDE MARKT 13
3000 Leuven
Belgium

See on map

Region
Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Myriam Witvrouw (Dr.)
Links
Total cost
No data

Participants (10)